Between 2018 and 2022, equity infusion has gone up to $6 billion from around $2 billion, the report from Elevation Capital found. However, 2023 overall has been a slow year in terms of venture funding.
Revenues have grown at a CAGR of 19% over the last 4 fiscal years to ₹4,077 crore. Net profit has grown at 32% during this period to ₹158 crore in FY23. The Ebitda margin for FY23 is at 8.5% with return on net worth standing at 19% and return on capital employed at 14%.